{{Rsnum
|rsid=182784
|Gene=BMP7
|Chromosome=20
|position=57249477
|Orientation=plus
|GMAF=0.483
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=BMP7
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 27.4 | 56.6 | 15.9
| HCB | 62.8 | 31.4 | 5.8
| JPT | 57.5 | 35.4 | 7.1
| YRI | 4.1 | 29.3 | 66.7
| ASW | 3.5 | 42.1 | 54.4
| CHB | 62.8 | 31.4 | 5.8
| CHD | 59.6 | 31.2 | 9.2
| GIH | 34.7 | 47.5 | 17.8
| LWK | 5.5 | 49.1 | 45.5
| MEX | 24.1 | 44.8 | 31.0
| MKK | 7.1 | 30.1 | 62.8
| TSI | 27.5 | 52.9 | 19.6
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs182784
|Name_s=
|Gene_s=BMP7
|Feature=
|Evidence=PubMed ID:17537913
|Annotation=Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 87. Study population/ethnicity: 87 European descent Caucasians. Significance metric(s): p = 0.000008. Type of association: FA; GN.
|Drugs=etoposide
|Drug Classes=
|Diseases=Drug Toxicity
|Curation Level=Curated
|PharmGKB Accession ID=PA165109326
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs182784
|overall_frequency_n=42
|overall_frequency_d=90
|overall_frequency=0.466667
|n_genomes=28
|n_genomes_annotated=0
|n_haplomes=37
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}